Juno Therapeutics

Part of Bristol Myers Squibb

CompanyUnited StatesFounded 2013

Juno Therapeutics develops one asset, in phase 1 (JCARH125 in multiple myeloma). Mostly cell therapy acting on TNFRSF17; based in the United States, founded in 2013.

1
Asset
Furthest stage: Phase 1; 11
Trials: 0
Signals

Pipeline

1

JCARH125
BCMA-directed chimeric antigen receptor (CAR) T-cell therapy targeting multiple myeloma cells
Phase 1, Cell therapy, TNFRSF17, multiple myeloma

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms2
Trials15
Similar companies6